PLPP5
Summary:
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| phospholipid phosphatase 5 | MIM:610626 | Ensembl:ENSG00000147535 | HGNC:HGNC:25026 | PA142671154 | 8p11.23 |
GO terms in PLPP5
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IBA | GO:0008195 | phosphatidate phosphatase activity |
| MF | IDA | GO:0008195 | phosphatidate phosphatase activity |
| MF | IBA | GO:0016791 | phosphatase activity |
| CC | TAS | GO:0005737 | cytoplasm |
| CC | TAS | GO:0005886 | plasma membrane |
| CC | IBA | GO:0005887 | integral component of plasma membrane |
| BP | IBA | GO:0006644 | phospholipid metabolic process |
| BP | IBA | GO:0007165 | signal transduction |
| BP | IBA | GO:0046839 | phospholipid dephosphorylation |
| BP | IDA | GO:0046839 | phospholipid dephosphorylation |
Gene expression in normal tissue: PLPP5
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in PLPP5
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| reactome | R-HSA-168249 | Innate Immune System |
| reactome | R-HSA-168256 | Immune System |
| reactome | R-HSA-2029480 | Fcgamma receptor (FCGR) dependent phagocytosis |
| reactome | R-HSA-2029485 | Role of phospholipids in phagocytosis |
| kegg | hsa00561 | Glycerolipid metabolism - Homo sapiens (human) |
| kegg | hsa00564 | Glycerophospholipid metabolism - Homo sapiens (human) |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD318 | PAC-1 | 6 |
| iGMDRD885 | Compound 110 | 3 |
| iGMDRD781 | Sirolimus | 6 |
| iGMDRD267 | Oligomycin A | 3 |
| iGMDRD427 | ABT737 | 3 |
| iGMDRD889 | Compound 7d-cis | 3 |
| iGMDRD420 | Leucascandrolide A | 6 |
| iGMDRD486 | Tosedostat | 3 |
| iGMDRD435 | BI-2536 | 6 |
| iGMDRD300 | Tozasertib | 3 |
| iGMDRD886 | Compound 1541A | 3 |
| iGMDRD505 | Pevonedistat | 3 |
| iGMDRD506 | Fedratinib | 9 |
Gene in drug-gene network: Network Plot

Gene-drug targets distribution
Gene Structure: PDB
Models in PLPP5

